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ABSTRACT  1 
Purpose: Recent research suggests that acute consumption of pharmacological analgesics can 2 
improve exercise performance, but the ergogenic potential of ibuprofen (IBP) administration 3 
is poorly understood. This study tested the hypothesis that IBP administration would enhance 4 
maximal exercise performance. Methods: In one study, 13 physically active males completed 5 
60 × 3-s maximum voluntary contractions (MVC) of the knee extensors interspersed with a 6 
2-s passive recovery period, on two occasions, with the critical torque (CT) estimated as the 7 
mean torque over the last 12 contractions (part A). In another study, 16 active males 8 
completed two 3-min all-out tests against a fixed resistance on an  electrically-braked cycle 9 
ergometer with the critical power (CP) estimated from the mean power output over the final 10 
30-s of the test (part B). All tests were completed 60 min after ingesting maltodextrin 11 
(placebo, PL) or 400 mg of IBP. Peripheral nerve stimulation was administered at regular 12 
intervals and electromyography was measured throughout. Results: For part A, mean torque 13 
(IBP: 60±12 vs. PL: 58±14% of pre-exercise MVC) and CT (IBP: 40±15 vs. PL: 41±16% of 14 
pre-exercise MVC) were not different between conditions (P>0.05). For part B, end-test 15 
power output (IBP: 292±28 W vs PL: 288±31 W) and work done (IBP: 65.9±5.9kJ vs PL: 16 
65.4±6.4kJ) during the 3-min all-out cycling tests were not different between conditions (all 17 
P>0.05). For both studies, neuromuscular fatigue declined at a similar rate in both conditions 18 
(P>0.05). Conclusion: Acute ingestion of 400 mg IBP does not improve single-leg or 19 
maximal cycling performance in healthy humans.  20 
 21 
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INTRODUCTION 24 
Ibuprofen (IBP), a non-steroidal anti-inflammatory drug (NSAID) predominantly used to 25 
treat pain and reduce inflammation and fever, is considered safe for oral ingestion within 26 
healthy populations at the standard therapeutic dose (Albert & Gernaat, 1984; García-Martín 27 
et al. 2004). Consequently, utilisation of analgesic (i.e., pain relieving) and anti-inflammatory 28 
medication, such as IBP, has emerged as a popular pre-competition strategy in elite athletes 29 
attempting to enhance athletic performance (Alaranta et al. 2008; Corrigan & Kazlauskas, 30 
2003; Da Silva et al. 2015; Gorski et al. 2011; Huang et al. 2006). It is believed that NSAIDs 31 
act centrally and peripherally to reduce the perception of pain and tissue inflammation, 32 
respectively (Friden & Lieber, 1992). The therapeutic effect of NSAIDs in treating 33 
inflammation and pain has largely been ascribed to inhibited synthesis of prostaglandins (i.e. 34 
PGE2, Friden & Lieber, 1992). Specifically, IBP limits the metabolism of arachidonic acid, a 35 
precursor for the synthesis of prostaglandins, by inhibiting the enzyme, cyclooxygenase 36 
(Albert & Gernaat, 1984).   37 
  38 
Following the onset of muscle contractions, changes in contraction-induced mechanical 39 
stimuli and noxious chemicals (including an increased PGE2 release) activate and/or sensitise 40 
molecular receptors located on the terminal end of group III and IV nerve fibers, contributing 41 
to an increased sensation of muscle pain during exercise (O’Connor & Cook, 1999; McCord 42 
& Kaufmann, 2010; Pollak et al. 2014). The activation of these receptors appears to play a 43 
role in neuromuscular fatigue development through modulating both central and peripheral 44 
fatigue. Indeed, when the ascending projection of group III and IV muscle afferents is 45 
attenuated via intrathecal fentanyl administration, central motor drive is increased (as inferred 46 
via electromyography, EMG) and peripheral fatigue development is expedited (Amann et al. 47 
2009, 2011; Blain et al. 2016).  Therefore, it is possible that an intervention that is able to 48 
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reduce the magnitude of afferent feedback, such as NSAID administration, may attenuate the 49 
decline in skeletal muscle activation during intense exercise and thus improve exercise 50 
performance (Amann & Calbet, 2008; Morgan et al. 2018a; Morgan et al. 2018b). Indeed, 51 
elevating the magnitude of muscle afferent feedback is known to impair endurance exercise 52 
capacity (i.e. Amann et al. 2013). 53 
 54 
Acute consumption of analgesics (e.g. acetaminophen, ACT) has been shown to improve 55 
exercise performance (Foster et al. 2014; Mauger et al. 2010; Morgan et al 2018a; Morgan et 56 
al. 2018b). Mauger et al. (2010) administered an acute dose of 1.5 g ACT to trained cyclists 57 
and reported a 2% improvement in 16.1-km time-trial (TT) performance. Moreover, an acute 58 
dose of ACT has been shown to improve exercise tolerance in the heat (Mauger et al. 2014), 59 
repeated sprint performance (Foster et al. 2014), repeated maximal voluntary contraction 60 
(MVC) performance of the knee extensors (Morgan et al. 2018a) and maximal cycling 61 
performance (Morgan et al. 2018b). However, while these studies suggest that oral 62 
administration of a commercially-available pharmaceutical analgesic can delay fatigue 63 
development and improve exercise performance (Foster et al. 2014; Mauger et al. 2010; 64 
Morgan et al 2018a, b), the ergogenic effects of IBP are unclear despite widespread use of 65 
IBP as a putative performance aid (Cleak, & Eston. 1992; Nosaka & Clarkson, 1996). 66 
 67 
In contrast to the effects of ACT consumption on exercise performance, there is currently 68 
very limited published research on NSAID and NSAID-like compounds during exercise 69 
when muscle damage is not present. Despite the prevalence of its use amongst athletic 70 
populations, it is unclear whether IBP will provide an ergogenic benefit to performance in a 71 
‘fresh’ state. Other NSAID-like compounds have elicited no ergogenic effect on endurance 72 
performance (e.g., aspirin, Cook et al. 1997; ginger, Black & O’Connor, 2008). In contrast, 73 
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enhanced aerobic exercise performance following caffeine ingestion has been related, at least 74 
in part, to altered pain perception and enhanced endurance performance (e.g., Gonclach et al. 75 
2016). In addition, whilst exercise has been shown to increase PGE2 release (Trappe et al. 76 
2001; Novak & Wennmalm, 1979; Wilson & Kapoor, 1993; Vinikka et al. 1984), the extent 77 
to which it plays an important role, especially following interventions aimed at reducing 78 
PGE2 synthesis, during endurance exercise in the absence of muscle damage is unclear.  79 
   80 
The purpose of this study was to test the hypotheses that, compared to a placebo, acute 81 
consumption of 400 mg IBP would increase total work done, and reduce the rate of fatigue 82 
development by enabling a better maintenance of muscle activation during exercise. Two 83 
studies are presented using two different types of exercise: a 5-min single-leg intermittent 84 
MVC test and a 3-min maximal whole body cycling test to provide a more comprehensive 85 
understanding of the ergogenic potential of IBP.  86 
 87 
MATERIALS AND METHODS  88 
Participants 89 
Two independent groups of thirteen recreationally-active males (mean ± SD: age 31 ± 7 90 
years, height 1.76 ± 0.08 m, body mass 75 ± 11 kg), and sixteen recreationally-active males 91 
(mean ± SD: age 29 ± 9 years, height 1.79 ± 0.07 m, body mass 77 ± 8 kg, V̇O2peak 60.8 ± 7.8 92 
ml·kg-1·min-1), volunteered for the first (A) and second (B) part of this study, respectively. 93 
All participants provided written, informed consent to participate in this study, which was 94 
approved by the Sport and Health Sciences Ethics Committee at the University of Exeter. 95 
After being informed of the experimental procedures and associated risks, all participants 96 
completed a medical health questionnaire to ensure it was safe for them to consume IBP prior 97 
to performing exhaustive exercise, due to the potential contraindications associated with IBP 98 
6 
 
ingestion. Participants were not consumers of any ‘pain relief’ or anti-inflammatory 99 
medication (prescription or non-prescription) over the course of the study. None of the 100 
participants had a history of motor or neurological disorders. Participants were instructed to 101 
arrive at the laboratory in a rested and fully hydrated state, at least 3 h post-prandial, and to 102 
avoid strenuous exercise and refrain from consuming caffeine and alcohol in the 24 h 103 
preceding each testing session. Participants were also instructed to consume their habitual 104 
diet and continue normal training activities for the experimental period. For part A and B, 105 
participants recorded their diet and physical activity for 7 d prior to the first experimental 106 
visit and then replicated this for all remaining experimental visits.  107 
 108 
Experimental Design 109 
Both protocols (part A and B) followed identical experimental designs to previous research 110 
conducted within our laboratory (Morgan et al. 2018a, 2018b). For part A (Morgan et al. 111 
2018a), participants visited the laboratory on three occasions over a 3-4 week period with 112 
tests being conducted on an isokinetic dynamometer (Biodex System 3, Shirley, NY, USA). 113 
For part B (Morgan et al. 2018b), participants visited the laboratory on five occasions over a 114 
5-6 week period and tests were conducted on an electronically braked cycle ergometer (Lode 115 
Excalibur Sport, Groningen, the Netherlands). Experimental tests were separated by at least 116 
7, but no more than 9, days (part A) and for at least 72 h (part B), and were completed at a 117 
similar time of day (± 90 mins). The first laboratory visits for each study were used to 118 
familiarise participants to the measurements and experimental protocols described below. 119 
Subsequently, participants performed the fatiguing protocol (s) under two conditions (see 120 
‘Experimental Protocol’): placebo (PL) and IBP.  121 
 122 
Experimental Protocol A (60 MVC protocol) 123 
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The isokinetic dynamometer was initially adjusted so that the axis of rotation of the lever arm 124 
was in line with the lateral epicondyle of the right femur. Participants were seated with the 125 
hip and knee joints at relative angles of 155° and 90°, respectively. The remainder of the 126 
chair settings were recorded (during familiarisation) and replicated in all subsequent tests to 127 
ensure identical body position throughout the experimental trials. Inelastic padded Velcro 128 
straps were fastened at the ankle, quadriceps, hip and shoulders to maintain a stable body 129 
position.  130 
 131 
Following the familiarisation trial, visits 2 and 3 were completed in a double-blind, 132 
randomised fashion using a cross-over experimental design. 1000 mg of maltodextrin 133 
(placebo) or 400 mg IBP (combined with 600 mg maltodextrin) was ingested orally, 60 134 
minutes prior to the exercise bout such that the start of the exercise trial was expected to 135 
coincide with peak plasma [ibuprofen] concentration (Janssen & Venema, 1985). For IBU, 2 136 
identical capsules containing 200 mg ibuprofen and 300 mg maltodextrin each were ingested. 137 
The placebo was made from dextrose powder inserted into 2 gelatine capsules (500 mg in 138 
each capsule) designed to have a similar appearance and the weight to IBU capsules. The 139 
trials started with a standardised isometric warm-up routine (10 isometric contractions for 3 s 140 
at 50% of pre-exercise MVC as measured during familiarisation testing) and testing of the 141 
optimal EMG electrode, anode, and cathode placement and stimulation intensity for 142 
peripheral nerve stimulation. The experimental protocol consisted of 60 brief MVCs (3 s 143 
contraction, 2 s rest), in response to a visual prompt to ‘go’ and ‘relax’, accompanied by the 144 
same verbal instructions from the experimenter. Every 6th contraction was accompanied by 145 
peripheral nerve stimulation during and 1 s post MVC (as described for pre-trial 146 
measurements below). Participants were not made aware of the time or the number of MVCs 147 
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that had elapsed during the protocol and were instructed to continue to perform maximal 148 
contractions throughout. 149 
 150 
Experimental protocol B (3-min cycling test) 151 
For the 3-min cycling protocol, participants initially completed an incremental ramp test to 152 
exhaustion for the determination of gas exchange threshold (GET), linear factor, peak aerobic 153 
power output and peak oxygen uptake V̇O2peak as previously described (Black et al. 2014; 154 
Morgan et al. 2018b). The fixed resistance for the 3-min cycling protocol was set using the 155 
linear mode (i.e. linear factor) of the ergometer such that on reaching their preferred cadence, 156 
the participants would achieve a power output equivalent to 50% of the difference between 157 
GET and V̇O2peak (linear factor = 50%∆ peak aerobic power output/preferred cadence2). 158 
During this visit, the seat and handlebar positions were adjusted for comfort and replicated 159 
for all tests. During the second and third laboratory visits, participants completed a 3-min all-160 
out test with these serving as familiarization trials to the experimental protocol as described 161 
below and to ensure the coefficient of variation for work done and critical power (CP) 162 
between visits was <1%. Participants then performed the 3-min all-out cycling test under two 163 
conditions: placebo (PL) and IBP.  164 
 165 
The experimental protocol consisted of a 3-min period of unloaded pedalling at each 166 
participant’s preferred cadence (85-100 rpm), followed by a 3-min all-out sprint, 60 min 167 
following ingestion of either placebo (1000 mg maltodextrin) or 400 mg of IBP. The order of 168 
trials on visits 4 and 5 were administered in a double-blind, randomised fashion using a cross-169 
over experimental design. The 3-min all-out cycling protocol used in this study replicated the 170 
procedures described previously by Vanhatalo et al. (2007, 2008).  171 
 172 
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Neuromuscular function (Parts A and B) 173 
For part A and B, neuromuscular function was assessed pre-, during- and post-trial (< 10 s). 174 
Single peripheral nerve stimulation pulses were manually triggered at rest to determine pre-175 
exercise neuromuscular function, namely the characteristics of the M-wave response (M-176 
wave amplitude; Mmax) to supra-maximal nerve stimulation, voluntary activation (for part A 177 
only) and potentiated twitch torque (pTw, for part A only). During MVCs, peripheral nerve 178 
stimulation pulses were triggered to occur as soon as a peak torque was achieved (typically 179 
1.5 s into a 3 s contraction) and were each separated by a 45 s rest period. The stimuli were 180 
also delivered 1-s after the cessation of the contraction to provide a resting pTw. Identical 181 
measurements were repeated as soon as possible (< 10s) after the fatiguing exercise to 182 
determine post-exercise neuromuscular function (see figure 1).  183 
 184 
Torque (Part A) 185 
For part A, knee-extensor torque from the Biodex isokinetic dynamometer was sampled at 186 
1000 Hz and low-pass filtered at 40 Hz, before being displayed on a wide screen monitor 187 
using Spike2 (CED, Cambridge, UK).  Torque was expressed throughout as a percentage (%) 188 
of initial pre-exercise MVC. 189 
 190 
Breath-by-breath pulmonary gas exchange (Part B) 191 
For the 3-min maximal cycling protocol, participants wore a face mask connected to an 192 
impeller turbine transducer assembly (Cortex Metalyzer, Cortex, Leipzig, Germany). Inspired 193 
and expired gas volume and concentration signals were continuously sampled at 100 Hz. The 194 
analyser was calibrated before each test with gases of known concentration, and a calibration 195 
syringe of known volume (3-L; Hans Rudolph, KS).  196 
 197 
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Electromyography (Parts A and B) 198 
For parts A and B, surface EMG activity was recorded from m.vastus lateralis, m.vastus 199 
medialis and m.rectus femoris of the quadriceps and m.biceps femoris of the hamstring of the 200 
right leg using active bipolar bar electrodes in a single differential configuration (DE2.1, 201 
DelSys Inc, Boston, MA, USA). The electrodes were placed over the respective muscle 202 
bellies (SENIAM guidelines). Double-sided adhesive tape and a hypoallergenic medical tape 203 
were used to ensure the EMG sensor stability. The skin area underneath each EMG electrode 204 
was shaved, then exfoliated and cleaned with alcohol to minimise the skin impedance. The 205 
EMG and torque signals were pre-amplified (1,000 x), band-pass filtered (20–450 Hz, 206 
Bagnoli-8, DelSys Inc, Boston, MA, USA), and then transferred to a computer with a 207 
sampling frequency of 2 kHz and high-pass filtered at 10 Hz. EMG and torque data were 208 
recorded continuously and digitised synchronously with 16 bit resolution via an A/D 209 
converter (±5 V range, CED 1401 power, Cambridge, UK). EMG was average rectified using 210 
the root mean square method (EMGRMS). EMGRMS was then normalised to the pre-exercise 211 
maximum (or maximal EMG signal) and the local M-wave amplitude (closest time point 212 
measure of the M-wave) in order to exclude any changes to the EMG trace to changes in 213 
local excitability. The ground electrode was placed over the patella of the right leg.  214 
 215 
Peripheral Nerve Stimulation (Parts A and B) 216 
Electrical stimulation was applied with a constant current stimulator (Digitimer Stimulator 217 
DS7A, Digitimer, UK) for the assessment of M-waves (parts A and B) and potentiated twitch 218 
force (part B). M-waves were elicited by supramaximal percutaneous electrical stimulation of 219 
the femoral nerve (200 μs duration). The cathode was placed over the femoral nerve in the 220 
inguinal fossa, approximately 3–5 cm below the inguinal ligament in the femoral triangle. 221 
The cathode was systematically moved vertically and horizontally and the amplitude of the 222 
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muscle action potential (i.e. M-wave) was monitored to identify the optimal position of the 223 
cathode for attaining maximal peak-to-peak M-wave amplitude. Once the M-wave was 224 
elicited, the maximum amplitude (peak-to-peak) of the M-wave was determined (Mmax) for 225 
the vastus lateralis and vastus medialis. To determine the stimulation intensity, single stimuli 226 
were delivered in 20 mA step-wise increments from 100 mA until a plateau in quadriceps 227 
pTw (part A only) and M-wave were observed. To ensure a supramaximal response, the 228 
current was increased by an additional 30% (mean ± SD current = 214 ± 66 mA; 251 ± 46 229 
mA, part A and B, respectively). The average Mmax was obtained from 3 stimuli, with ~8-10 s 230 
separating each pulse at rest. For the 3-min maximal cycling protocol, single peripheral nerve 231 
stimulation pulses were manually triggered at ‘rest’ (defined as 80 rpm at 20 W) to determine 232 
pre-exercise neuromuscular function. Initially, the crank angle at which peripheral nerve 233 
stimulation was to be delivered during the trials was determined for each subject as described 234 
by Black et al. (2014) and as performed by Sidhu et al. (2012). Peripheral nerve stimulation 235 
pulses were triggered to coincide with maximal muscle activation around the crank cycle 236 
(typically around 50-60º from top-dead centre) 3 times, randomly, during a 10 s period using 237 
a custom written sequencer script. Identical measurements were repeated every 30 s in the 238 
all-out sprint.  239 
 240 
Data Analyses 241 
Data were analysed using a custom written script developed in Spike2 software (CED, 242 
Cambridge, UK). For part A, mean torque for each 3 s contraction during the 60 MVC 243 
protocol was determined as the mean value over a 1-s period which approximated the plateau 244 
level of the highest torque (i.e. 500 ms before and after the peak torque). The pTw was 245 
calculated as the peak torque achieved following the single pulse delivered 1-s post-MVC. 246 
The twitch torque superimposed onto the peak force production of the MVC (sTw) was 247 
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calculated as the increment in torque immediately following the pulse during MVCs. The 248 
end-test torque (i.e. critical torque, CT) during the 60 MVC test was defined as the mean of 249 
the last 12 contractions (i.e., the last 60 s; Burnley, 2009; Morgan et al. 2018a). The torque-250 
impulse was calculated as the area under the torque-time curve by accumulating the time 251 
integral of each MVC (3 s).  252 
 253 
Voluntary activation (VA, %) was calculated using the interpolated twitch method from 254 
peripheral nerve stimulation (Merton, 1954; Goodall et al. 2010). Specifically, the increment 255 
in torque evoked during the MVCs was expressed as a fraction of the amplitude of the 256 
potentiated twitch produced with the same stimulus in the relaxed muscle post-MVC. The 257 
level of voluntary drive was then quantified as a percentage: [1 – evoked torque 258 
(superimposed on voluntary torque, sTw)/ (mean control evoked response, pTw) × 100] (i.e., 259 
Allen at al. 1998). The changes in voluntary torque and pTw, were used to assess global 260 
fatigue and peripheral fatigue, respectively with VA, MMax and EMGRMS used to assess 261 
central fatigue.  The maximal EMG was taken from the first MVC during the 60 MVC task 262 
and compared to the last MVC at task end. The neuromuscular parameters extracted from the 263 
three sets of maximal contractions completed post-exercise were tested for statistical 264 
differences between sets of contractions and then compared to the first set of MVCs 265 
completed pre-exercise (Froyd et al. 2013; Pageaux et al. 2015; Doyle-Baker et al. 2017). 266 
Neuromuscular function was also measured for each of the stimulated contractions during the 267 
exercise and normalised to the corresponding pre-exercise values at 100% MVC.  268 
 269 
For the 3-min cycling protocol (part B), the end-test power (i.e. CP) during the 3-min test was 270 
defined as the mean of the last 30 s (Vanhatalo et al. 2007; 2008). The Wʹ was calculated as 271 
the area above the CP from the power-time curve. Power output was recorded second-by-272 
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second, and the peak power was determined as the highest 1-s value. The changes in power 273 
output, MMax and EMGRMS, were used to quantify neuromuscular fatigue development and 274 
changes in muscle activation. Peak V̇O2 was determined as the highest value recorded in a 275 
15-s interval. The achievement of V̇O2peak was an essential criterion for a valid 3-min test. All 276 
neuromuscular parameters and torque were averaged across the protocol using 30-s bin 277 
averages. 278 
 279 
Statistics 280 
Paired-samples t-tests were used to compare the mean torque, total work done, CT, Wʹ and 281 
pTw between IBP and PL in part A. In addition, paired-samples t-tests were used to compare 282 
the total work done, CP, Wʹ and cardiorespiratory responses between IBP and PL obtained 283 
from the 3-minute maximal cycling test. For the 60 MVC test, the profiles of VA and M-284 
wave amplitude were analysed using two-way ANOVAs with repeated measures (using 12 285 
contraction averages; i.e. 6 time points). In addition, a two-way ANOVA with repeated 286 
measures (condition × work rate) was used to assess differences in end exercise V̇O2 and the 287 
profiles of EMG and M-wave amplitude. Normalised EMGRMS were analysed using two-way 288 
ANOVAs with repeated measures using 30-s means (i.e. 10 time points). Where sphericity 289 
was violated, Greenhouse-Geisser correction factor was used. For all tests, results were 290 
considered statistically significant when P<0.05. Data are presented as means ± SD unless 291 
otherwise indicated. All statistical analyses were conducted using IBM SPSS Statistics 292 
version 23. 293 
 294 
RESULTS 295 
Part A (60 MVC test) 296 
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The mean MVC torque achieved prior to the 60 MVC protocol was 232 ± 47 and 230 ± 297 
55 N.m for PL and IBU, respectively. VA of the knee extensors achieved during the 298 
preliminary MVCs was 88 ± 7 and 89 ± 6% for PL and IBU, respectively. Baseline MVC and 299 
VA were not different between conditions (P>0.05). The profile for mean torque during each 300 
contraction across all participants for the 60 MVC protocol is illustrated in figure 2a. During 301 
the PL trial, torque declined from a peak of 99 ± 3% MVC (relative to pre-exercise MVC) 302 
during the first contraction to 40 ± 15% MVC during the last 12 contractions (P<0.01, Table 303 
1, figure 2a). During the IBP trial torque declined from a peak of 99 ± 3% to 41 ± 16% MVC. 304 
The mean torque (relative to pre-exercise MVC) achieved across the 60 MVCs not different 305 
with IBP (60 ± 13%, 87.1 ± 22.2 N.m,) compared to PL (58 ± 14%, 83.8 ± 22.7 N.m, 306 
P=0.39). There was no difference in CT (PL: 40 ± 15% vs. IBP: 41 ± 16%. P=0.74), Wʹ (PL: 307 
6.97 ± 2.43 vs. IBP: 7.23 ± 3.57 N.m.s; P=0.69) or total impulse, the surrogate measure of 308 
total work done (PL: 22,055 ± 3,885 vs. IBP: 22,919 ± 3,394 N.m.s; P=0.26) between the PL 309 
and IBP conditions.  310 
 311 
Part A (Neuromuscular Function) 312 
Alongside the decline in voluntary force (figure 2a), pTw (figure 3a), VA (figure 3b), 313 
EMGRMS (figure 3c) and MMax (figure 3d) were also reduced as protocol A progressed (main 314 
effect of time, all P<0.01). There were no differences between PL and IBP in pTw, VA, 315 
EMG amplitude or M-wave amplitude at any time point (all P>0.05). pTw declined from 63 316 
± 14 to 30 ± 21 N·m and from 68 ± 17 to 31 ± 23 N·m, VA declined from 89 ± 8 to 59 ± 19% 317 
and from 88 ± 7  to 60 ± 18%, EMG declined from 99 ± 4 to 59 ± 17% and 100 ± 2 to 64 ± 318 
20% (from first 6 to last 6 contractions) and M-wave amplitude declined from 100 ± 1 to 96 ± 319 
14% and 100 ± 1 to 95 ± 12% in the PL and IBP conditions, respectively (P<0.05), with no 320 
differences between PL and IPB for any of these variables (P>0.05).  321 
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 322 
Part B (3-min cycling test) 323 
The mean power output profile for all participants during the 3-min all-out cycling test is 324 
shown in figure 2b for the PL and IBP conditions. During the PL trial, power output declined 325 
from 820 ± 139 W to 288 ± 31 W during the last 30 s of the 3-min test (P<0.01; table 1, 326 
figure 2b). During the IBP trial, power output declined from 816 ± 131 W to 292 ± 28 W 327 
during the last 30 s of the 3-min test. There were no differences in CP (PL: 288 ± 31 vs. IBP: 328 
292 ± 28 W, P=0.11), total work done (PL: 65.4 ± 6.4 vs. IBP: 65.9 ± 5.9 kJ, P=0.11) or Wʹ 329 
(PL: 13.6 ± 2.4 vs. IBP: 13.7 ± 2.8 kJ, P=0.84) between conditions.  330 
 331 
Part B (Neuromuscular Function) 332 
Similar to the 60 MVC protocol, alongside the decline in power output, there was a 333 
progressive decline in M-wave (P<0.01, figure 4b) and EMG amplitudes (P<0.01, figure 4a). 334 
The profiles of the M-wave and EMG amplitudes were not altered following IBP ingestion at 335 
any time point (both P>0.05). Using 30 s mean values, EMG decreased from 94 ± 4 to 54 ± 336 
17% and from 96 ± 6 to 57 ± 14% (figure 4b) in PL and IBP, respectively.  337 
 338 
DISCUSSION 339 
Contrary to our experimental hypotheses, the principal findings of this study were that acute 340 
ingestion of 400 mg of IBP in a ‘fresh’ state had no effect on fatigue development or 341 
neuromuscular function during either a 5-min single-leg intermittent MVC test or a 3-min 342 
maximal cycling test. Across both protocols, power output and torque declined, and 343 
neuromuscular fatigue was evident in both the IBP and PL conditions.  However, there were 344 
no differences in CT or CP, total work done or neuromuscular fatigue markers between the 345 
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IBP and PL conditions.  These findings do not support the acute ingestion of IBP as a strategy 346 
to blunt fatigue development during exercise in healthy, recreationally active adults.  347 
 348 
Effects of acute IBP ingestion on exercise performance  349 
In contrast with our previous findings of improved CT and CP following the acute ingestion 350 
of ACT (Morgan et al. 2018a; Morgan et al. 2018b), these variables were not improved in the 351 
current study following the acute ingestion of IBP. However, our findings in the current study 352 
are in line with some previous observations that IBP ingestion does not improve performance 353 
during whole body exercise in humans (e.g., Cleak, & Eston. 1992; Da Silva et al. 2015; 354 
Nosaka & Clarkson, 1996; Tokmakdis et al. 2003). Previous studies that have reported 355 
improved exercise performance following IBP administration have typically assessed 356 
exercise performance following muscle damage. Nonetheless, while there is some evidence 357 
to suggest that the increases in muscle soreness, pain, damage and contractile dysfunction 358 
after contraction-induced muscle damage can be attenuated following NSAID administration 359 
(Ebbeling & Clarkson, 1989; Hasson et al. 1993; Pizza et al. 1999; Tokmakdis et al. 2003), 360 
there is also evidence that NSAID administration does not impact these variables after muscle 361 
damage is induced (Da Silva et al. 2015; Tokmakdis et al. 2003).  Taken together, these 362 
observations suggest that the ergogenic potential of administering IBP, a purported analgesic 363 
and anti-inflammatory agent (Friden & Lieber, 1992), is limited without prior induction of 364 
muscle damage, and even when muscle damage is induced, and inflammation and pain 365 
sensation are correspondingly increased, the effect of IBP ingestion on exercise performance 366 
is equivocal.    367 
 368 
One explanation for the lack of performance improvement following IBP ingestion in our 369 
study may be the reduced ability to regulate the distribution of effort (i.e., pacing strategy) in 370 
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the maximal protocols employed in response to a potential modulation of pain.  For example, 371 
Mauger et al. (2010) reported that pain` sensation was reduced (i.e., a greater power output 372 
was possible for the same pain sensation) and cycling time trial performance was enhanced 373 
following ingestion of ACT. Similarly, Gonglach et al. (2016) reported that manipulating 374 
pain perception via caffeine ingestion lead to higher power outputs when participants were 375 
asked to pace their effort based upon pain perception. Therefore, we cannot exclude the 376 
possibility that IBP consumption could be ergogenic in situations wherein pacing strategy is 377 
self-selected such as during longer duration endurance exercise.  378 
 379 
Another possible explanation for the absence of an ergogenic effect of IBP in our study is that 380 
inhibiting cyclooxygenase may induce secondary effects that may limit the cardiopulmonary 381 
response to exercise (Takayama et al. 2002) including a reduction in exercise-induced 382 
hyperaemia (Bradford et al. 2007; Scharage et al. 2004).  If skeletal muscle perfusion was 383 
impaired following IBP ingestion as a function of cyclooxygenase inhibition (Albert & 384 
Gernaat, 1984), this could have negated any potential ergogenic effects following IBP 385 
ingestion. However, given that performance was not enhanced during either smaller (single-386 
leg exercise) or larger (double leg cycling) muscle mass exercise following acute IBP 387 
ingestion in the current study, and that skeletal muscle perfusion is less likely to be a limiting 388 
factor for performance in a single leg model (Joyner & Casey, 2015), this seems unlikely.    389 
 390 
Effects of acute IBP ingestion on neuromuscular function 391 
The ingestion of 400 mg of IBP was not associated with attenuation of neuromuscular fatigue 392 
development as estimated with peripheral muscle excitability (part A and B), voluntary 393 
activation (part A), potentiated twitch (part A) or EMG amplitude (part A and B), consistent 394 
with the lack of change in exercise performance. We previously investigated the influence of 395 
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acute ingestion of 1 g of ACT on neuromuscular function during exercise and reported that, 396 
whilst EMG declined across the 3-min cycling protocol in both conditions, EMG declined to 397 
a lesser extent in the ACT (~72 %) compared to the PL (~54 %) condition (Morgan et al. 398 
2018b). The magnitude of this effect was remarkably similar to the results we obtained 399 
during a 60 MVC protocol completed in a single leg exercise model (ACT: 87% vs. PL: 59 400 
%, Morgan et al. 2018a). This observation suggests that improved maintenance of muscle 401 
activation contributed to the ergogenic effect of ACT (Morgan et al. 2018a). It is of interest, 402 
therefore, that similar effects were not evident following IBP ingestion. We are not aware of 403 
any research to suggest that ACT acts as a more potent stimulus to reduce pain sensation or 404 
alter muscle activation. However, it is possible that a combination of the higher ACT dose 405 
administered (1000 mg vs 400 mg for IBU), ACT’s potential as an antipyretic (Foster et al. 406 
2014) and differences in pharmacokinetics (Anderson, 2008; Albert & Gernaat, 1984) may 407 
have contributed to the disparate effects of IBP in our current study and ACT in our previous 408 
studies (Morgan et al. 2018a; Morgan et al. 2018b) on exercise performance and 409 
neuromuscular fatigue development. It is also pertinent to note that ACT ingestion has been 410 
reported to increase corticospinal excitability at rest, a factor which may contribute to its 411 
ergogenic potential (Mauger & Hopker, 2013).  412 
 413 
Experimental considerations 414 
Whilst our study contributes to a further understanding of the effect of IBP on exercise-415 
induced fatigue and some of its underlying mechanisms, there are some limitations that 416 
require consideration. Firstly, it is acknowledged that we did not measure pain sensation or 417 
biomarkers of inflammation. Pain was not assessed due to the protocols requiring the 418 
completion of maximal exercise. Asking participants to rate pain sensation may have 419 
compromised their ability to focus on the exercise task and to provide a true maximal effort. 420 
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The effect of IBP on exercise performance when pacing is permitted, and the individual can 421 
adjust their pacing strategy in response to potential differences in pain sensation, warrants 422 
further investigation. In addition, the extent to which prostaglandin synthesis during 423 
endurance exercise plays a role in pain perception in the absence of muscle damage requires 424 
further consideration. It is also important to point out that individuals intending to ingest IBP 425 
need to consider its potential side effects and be aware that it could impair the adaptive 426 
response to exercise (Schoenfield, 2012) and aspects of the beneficial remodelling of skeletal 427 
muscle to exercise training (Mikkelsen, 2009).  Therefore, individuals wishing to explore the 428 
use of pain relievers to enhance exercise performance should do so infrequently, with 429 
caution, and at the recommended therapeutic doses.  430 
 431 
Conclusion 432 
Acute ingestion of IBP did not attenuate the decline in neuromuscular function or improve 433 
CT or CP during a 60 MVC protocol of the knee extensors or a 3-min maximal cycling test. 434 
Therefore, our results indicate that IBP ingestion does not attenuate neuromuscular fatigue 435 
development, during either single-limb or whole-body cycling exercise, and do not support 436 
IBP ingestion as an ergogenic aid.   437 
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Tables   668 
Table 1: Performance and neuromuscular function parameters of the 60 MVC 
(protocol A) and 3-min all-out cycling (protocol B) tests following placebo and 
ibuprofen ingestion. 
 
 
 
Placebo (PL) 
 
Ibuprofen (IBU) 
Protocol A 
Performance 
  
Peak MVC (N.m) 232 ± 47 230 ± 55 
Mean torque (% MVC) 58 ± 14 60 ± 13 
Total Impulse (N.m.s) 22055 ± 3885 22919 ± 3394 
Critical torque, CT (% MVC) 40 ± 15 41 ± 16 
Wʹ (N.m.s-1) 6971 ± 2432 7231 ± 3570 
   
Neuromuscular function   
Change in pTw (N.m) 44 ± 27 43 ± 25 
End-exercise pTw (N.m) 30 ± 21 31 ± 23 
End-exercise VA (%) 59 ± 19 60 ± 18 
End-exercise M-wave amplitude (%) 96 ± 14 95 ± 12 
End-exercise EMG amplitude (%) 59 ± 17 64 ± 20 
Protocol B 
Performance 
  
Peak power output (W) 820 ± 139 816 ± 131 
Total Work Done (kJ) 65.4 ± 6.4 65.9 ± 5.9 
Critical power, CP (W) 288 ± 31 292 ± 28 
Wʹ (kJ) 13.6 ± 2.4 13.7 ± 2.8 
   
Neuromuscular function   
End-exercise M-wave amplitude (%) 84 ± 21 83 ± 18 
End-exercise EMG amplitude (%) 54 ± 17 57 ± 14 
 
 
MVC, maximal voluntary contraction; CT, critical torque measured in the last 6 contractions; 
CP, critical power measured in the last 30 s of the 3-minute maximal cycling test; pTw, 
potentiated twitch force; VA, voluntary activation measured using the interpolated twitch 
method technique; EMG, electromyography; N.m, newton metres; N.m.s-1, newton metres 
per second; ms, milliseconds. 
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Figure captions  669 
Figure 1 670 
Schematic of the procedures used prior to (panel a), during (panel b) and within 10 s 671 
following (panel c) the 60 maximal isometric voluntary contraction (MVC) protocol. 10 s 672 
separated each single pulse stimulation administered at rest (small dashed arrows). A, C 45 s 673 
rest period separated maximal efforts (MVCs). Single pulse stimuli were administered during 674 
peak force production of MVCs (large solid arrow) and immediately (<1-s) post MVCs 675 
(small grey arrows). B: 60 MVC protocol of the knee extensors. The figure presents a period 676 
of 30 s which is repeated sequentially for 5 min. Each MVC was held for 3 s and interspersed 677 
by a 2 s passive recovery period. Every 6th MVC was accompanied by single pulse stimuli 678 
administered during peak force production (large solid arrow) and immediately following (>1 679 
s) post MVCs (small grey arrows). This cycle was repeated 10 times such that the protocol 680 
spanned 5 minutes requiring the completion of 60 MVCs. Surface electromyography (EMG) 681 
was measured throughout.  682 
 683 
Figure 2 684 
The torque profile during the 60 maximal contractions for placebo (PL, clear circles) and 685 
ibuprofen (IBU, filled circles) trials in protocol (a) is demonstrated in panel A. The torque 686 
during all contractions was normalized to a control maximal voluntary contraction (MVC) 687 
performed before the test commenced. Note that torque falls over the first ~150 s before 688 
reaching stable values between 240 and 300 s (the end-test torque; last 12 MVCs). Panel B 689 
illustrates the mean ± SE power output profile during the 3-min maximal cycling protocol for 690 
placebo (clear circles) and ibuprofen (filled circles) trials.  Note that power output falls over 691 
the first ~120-150 s before reaching stable values (the end-test power output; i.e. CP).  692 
 693 
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Figure 3 694 
Mean ± SE potentiated twitch (A), voluntary activation (B), and EMG amplitude (C) and M-695 
wave amplitude (D) responses during the 60 MVC test for placebo (clear circles) and 696 
ibuprofen (filled circles) trials for protocol a.  697 
 698 
Figure 4 699 
Mean ± SE M-wave amplitude (A) and EMG amplitude (B) responses during the 3-minute 700 
maximal cycling exercise for placebo (clear circles) and ibuprofen (filled circles) trials for 701 
protocol b. 702 
